Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Early Transtympanic Steroid Injection in Patients with ‘Poor Prognosis’ Idiopathic Sensorineural Sudden Hearing Loss

Zhou Y.a · Zheng H.a · Zhang Q.a · Campione P.A.b

Author affiliations

aDepartment of Otolaryngology, Head and Neck Surgery, Changhai Hospital, Shanghai, China; bDepartment of Otolaryngology, Head and Neck Surgery, Buffalo Medical Group, State University at Buffalo, Buffalo, N.Y., USA

Related Articles for ""

ORL 2011;73:31–37

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: June 07, 2010
Accepted: October 26, 2010
Published online: December 03, 2010
Issue release date: January 2011

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 3

ISSN: 0301-1569 (Print)
eISSN: 1423-0275 (Online)

For additional information: https://www.karger.com/ORL

Abstract

Objective: The present trial is aimed to evaluate the effectiveness of early transtympanic steroid injection in patients with ‘poor prognosis’ idiopathic sensorineural sudden hearing loss (ISSHL). Methods: Seventy-six patients, diagnosed as having ISSHL with ‘poor prognosis’, were randomized into a transtympanic group and a control group. Thirty-nine patients received conventional steroid treatment and 37 patients received 4 courses of additional transtympanic injections of methylprednisolone 7 days after conventional steroid treatment. Results: In the transtympanic group 45.9% of the patients had at least 15 dB improvement in pure tone average compared with 20.5% of the patients in the control group at the 8-week follow-up audiogram. In the transtympanic group 43.2% of the patients had an improvement of ≧15% in speech discrimination, compared with 17.9% of the patients in the control group 8 weeks after the treatment. The differences between the 2 groups were statistically significantly. Conclusion: The outcome was better for the patients with ‘poor prognosis’ ISSHL if the transtympanic steroid therapy could be applied early.

© 2010 S. Karger AG, Basel


References

  1. Hughes GB, Freedman MA, Haberkamp TJ, Guay ME: Sudden sensorineural hearing loss. Otolaryngol Clin North Am 1996;29:393–405.
  2. Mattox DE, Simmons FB: Natural history of sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol 1977;86:463–480.
  3. Van Wijck F, Staecker H, Lefebvre PP: Topical steroid therapy using the Silverstein Microwicktrade mark in sudden sensorineural hearing loss after failure of conventional treatment. Acta Otolaryngol 2007;1012–1017.
  4. Pitovski DZ, Drescher MJ, Drescher DG: Glucocorticoid receptors in the mammalian inner ear: RU 28362 binding sites. Hear Res 1994;77:216–220.
  5. Wilson WR, Byl FM, Laird N: The efficacy of steroids in the treatment of idiopathic sudden hearing loss: a double-blind clinical study. Arch Otolaryngol 1980;106:772–776.
  6. Shapira Y, Telischi FF: Tympanic membrane breakdown after intratympanic injection of steroids in irradiated ears. Otol Neurotol 2007;28:499–500.
  7. Plaza G, Herraiz C: Intratympanic steroids for treatment of sudden hearing loss after failure of intravenous therapy. Otolaryngol Head Neck Surg 2007;137:74–78.
  8. Parnes LS, Sun AH, Freeman DJ: Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 1999;109:1–17.
  9. Chandrasekhar SS, Rubinstein RY, Kwartler JA, Gatz M, Connelly PE: Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of facilitating agents. Otolaryngol Head Neck Surg 2000;122:521–528.
  10. Xenellis J, Papadimitriou N, Nikolopoulos T, Maragoudakis P, Segas J: Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngol Head Neck Surg 2006;134:940–945.
  11. Fisch U: Management of sudden deafness. Otolaryngol Head Neck Surg 1983;91:3–8.
  12. Fetterman BL, Saunders JE, Luxford WM: Prognosis and treatment of sudden sensorineural hearing loss. Am J Otol 1996;17:529–536.
  13. Stokroos RJ, Albers FW, Schirm J: The etiology of idiopathic sudden sensorineural hearing loss: experimental herpes simplex virus infection of the inner ear. Am J Otol 1998;19:447–452.
  14. García-Berrocal JR, Ramírez-Camacho R: Sudden sensorineural hearing loss: supporting the immunologic theory. Ann Otol Rhinol Laryngol 2002;111:989–997.
  15. Pitovski DZ, Drescher MJ, Drescher DG: High affinity aldosterone binding sites (type I receptors) in the mammalian inner ear. Hear Res 1993;69:10–14.
  16. Plaza G, Herráiz C: Intratympanic steroids for treatment of sudden hearing loss after failure of intravenous therapy. Otolaryngol Head Neck Surg 2007;137:74–78.
  17. Doyle KJ, Bauch C, Battista R, Beatty C, Hughes GB: Intratympanic steroid treatment: a review. Otol Neurotol 2004;25:1034–1039.
  18. Silverstein H, Choo D, Rosenberg SI, Kuhn J, Seidman M: Intratympanic steroid treatment of inner ear disease and tinnitus (preliminary report). Ear Nose Throat J 1996;75:468–471.
  19. Kopke RD, Hoffer ME, Wester D, O’Leary MJ, Jackson RL: Targeted topical steroid therapy in sudden sensorineural hearing loss. Otol Neurotol 2001;22:475–479.
  20. Chandrasekhar SS: Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation. Otol Neurotol 2001;22:18–23.
  21. Gianoli GJ, Li JC: Transtympanic steroids for treatment of sudden hearing loss. Otolaryngol Head Neck Surg 2001;125:142–146.
  22. Lefebvre PP, Staecker H: Steroid perfusion of the inner ear for sudden sensorineural hearing loss after failure of conventional therapy: a pilot study. Acta Otolaryngol 2002;122:698–702.
  23. Ho GM, Lin HC, Shu MT, Yang CC, Tsai HT: Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope 2004;114:1184–1189.
  24. Herr BD, Marzo SJ: Intratympanic steroid perfusion for refractory sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2005;132:527–531.
  25. Slattery WH, Fisher LM, Iqbal Z, Friedman RA, Liu N: Intratympanic steroid injection for treatment of idiopathic sudden hearing loss. Otolaryngol Head Neck Surg 2005;133:251–259.
  26. Dallan I, Bruschini L, Nacci A, Bruschini P, Traino C, Rognini F, Fattori B: Transtympanic steroids as a salvage therapy in sudden hearing loss: preliminary results. ORL 2006;68:247–252.
  27. Roebuck J, Chang CYJ: Efficacy of steroid injection on idiopathic sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2006;135:276–279.
  28. Haynes DS, O’Malley M, Cohen S, Watford K, Labadie RF: Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope 2007;117:2–15.
    External Resources
  29. Fitzgerald DC, McGuire JF: Intratympanic steroids for idiopathic sudden sensorineural hearing loss. Ann OtoI Rhinol Laryngol 2007;116:253–256.
  30. Kilic R, Safak MA, Oguz H, Kargin S, Demirci M, Samim E, Ozluoglu N: Intratympanic methylprednisolone for sudden sensorineural hearing loss. Otol Neurotol 2007:312–316.
  31. Dallan I, Vito AD, Fattori B, Casani P, Panicucci E, Berrettini S, Marchetti M, Nacci A: Intratympanic methylprednisolone in refractory sudden hearing loss: a 27-patient case series with univariate and multivariate analysis. Otol Neurotol 2010;31:25–30.
  32. Mohamed H, Dennis T: Issues, indications, and controversies regarding intratympanic steroid perfusion. Curr Opin Otolaryngol Head Neck Surg 2008;16:434–440.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: June 07, 2010
Accepted: October 26, 2010
Published online: December 03, 2010
Issue release date: January 2011

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 3

ISSN: 0301-1569 (Print)
eISSN: 1423-0275 (Online)

For additional information: https://www.karger.com/ORL


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.